Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.409NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.409NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.83NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.83NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.83NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.310NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.310NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.310NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.362.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.362.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.362.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.162NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.162NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.162NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Y.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Y.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Y.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.86NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.86NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.86NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.154NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.154NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.154NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.4.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.4.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.4.8NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
A.2.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.2.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.2.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.41NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.41NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.41NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.137NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.137NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.137NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.446NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.446NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.446NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.76 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.76 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.76 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.398NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.398NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.398NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.163NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.163NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.163NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
P.3 (Theta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.3 (Theta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.3 (Theta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used